Formononetin enhances the chemosensitivity of triple negative breast cancer via BTB domain and CNC homolog 1-mediated mitophagy pathways

Shan Li; Linlian  Zhu; Yufeng He; Ting Sun

doi:10.18388/abp.2020_6466

Formononetin enhances the chemosensitivity of triple negative breast cancer via BTB domain and CNC homolog 1-mediated mitophagy pathways

Shan Li Oncology Department, Dongtai People’s Hospital, Dongtai City, Jiangsu Province 224200, China https://orcid.org/0000-0003-4782-4018
Linlian Zhu Oncology Department, Dongtai People’s Hospital, Dongtai City, Jiangsu Province 224200, China
Yufeng He Oncology Department, Dongtai People’s Hospital, Dongtai City, Jiangsu Province 224200, China
Ting Sun Oncology Department, Dongtai People’s Hospital, Dongtai City, Jiangsu Province 224200, China

DOI: https://doi.org/10.18388/abp.2020_6466

Abstract

This study aimed to investigate the effects of formononetin on triple negative breast cancer (TNBC). Clinical samples were collected from patients with TNBC. Overall survival rates were evaluated using the Kaplan-Meier method. Gene expression was determined using immunohistochemistry, immunofluorescence and western blot. Cellular functions were determined using CCK-8, colony formation and propidium iodide (PI) staining. Xenograft assay was performed to further verify the effects of formononetin (FM) on TNBC. We found that FM combined therapy suppressed the metastasis of TNBC and increased the overall survival rates of TNBC patients. Moreover, FM suppressed the proliferation and induced mitochondrial damage and apoptosis of TNBC cells. FM increased the expression of the BTB domain and CNC homolog 1 (BACH1) in TNBC tissues as well as cells. However, BACH1 knockdown antagonized the effects of FM and promoted the survival of TNBC cells. FM suppressed the tumor growth of TNBC. Taken together, FM suppressed the aggressiveness of TNBC via BACH1/p53 signaling. Therefore, FM may be an alternative strategy for TNBC.

pdf
html

Published

2023-09-06

Issue

Vol. 70 No. 3 (2023)

Section

Articles

This work is licensed under a Creative Commons Attribution 4.0 International License.

Acta Biochimica Polonica is an OpenAccess quarterly and publishes four issues a year. All contents are distributed under the Creative Commons Attribution-ShareAlike 4.0 International (CC BY 4.0) license. Everybody may use the content following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.